
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Loading news...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Henry Schein, Inc. (NASDAQ: HSIC - Get Free Report) CEO Stanley Bergman sold 10,785 shares of the firm's stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $81.20, for a total transaction of $875,742.00. Following the transaction, the chief executive officer directly owned 309,092 shares in the company,

West Pharmaceutical Services (NYSE: WST - Get Free Report) and Henry Schein (NASDAQ: HSIC - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Valuation and Earnings This table compares West

Artisan Partners Limited Partnership raised its position in Henry Schein, Inc. (NASDAQ: HSIC) by 5.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,833,041 shares of the company's stock after purchasing an additional 370,837 shares during the quarter. Artisan Partners Limited

Henry Schein, Inc. (HSIC) Q4 2025 Earnings Call Transcript

Global Sales: $3.4 billion, growth of 7.7% compared to Q4 2024.GAAP Operating Margin: 4.76%, a decrease of 10 basis points year-over-year.Non-GAAP Operating Ma

Global Distribution and Value-Added Services sales rose 7.0% to $2.89 billion in the fourth quarter, up 5.2% on a constant-currency basis from the year-ago period.

The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Henry Schein tops Q4 estimates with 7.8% sales growth, but margin contraction tempers strong equipment, specialty and tech gains.

Henry Schein on Tuesday beat fourth-quarter profit estimates and forecast annual profit largely in line with Wall Street expectations on the back of stabilizing demand for its dental and medical equipment.

Henry Schein (HSIC) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.19 per share a year ago.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. “Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particularly our global equipment, specialty products and technology busi.

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the market leader in dental practice management systems, today announced the launch of AI-driven Image Verify, the latest innovation in a rapid series of product advancements designed to deliver the cleanest claims experience in dentistry. Image Verify, natively embedded in Dentrix and Dentrix Ascend, represents another major step towards the company's bold Clean Claims vision – a future where dental practices submit claims once and never.

Rhumbline Advisers trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ: HSIC) by 3.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 273,400 shares of the company's stock after selling 9,004 shares during the period. Rhumbline Advisers owned

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HSIC gears up for Q4 results, with revenues seen rising 4.5% and strength across dental, medical and tech segments shaping expectations.

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One today announced a direct data integration between Align Technology's iTero™ intraoral scanners and its core practice management platforms—Dentrix, Dentrix Ascend, and Dentally—creating a seamless connection between digital scanning, diagnosis, and daily operations for practices worldwide. Developed in collaboration with Align Technology, the integration automatically imports iTero scans into patient records, eliminating manual uploads, dupl.

HOUSTON--(BUSINESS WIRE)--The American Dental Association Foundation (ADAF) is officially kicking off Give Kids A Smile® (GKAS) 2026 at UTHealth Houston School of Dentistry, marking 24 years of transforming children's lives through this access-to-oral-health-care initiative. What began as a local grassroots movement in St. Louis, MO, has evolved into a national movement, having served more than 10.2 million underserved children since 2003. GKAS begins nationally in February, which is National C.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the B.

Dilation Capital Management LP bought a new stake in Henry Schein, Inc. (NASDAQ: HSIC) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 76,920 shares of the company's stock, valued at approximately $5,105,000. Henry Schein accounts for 2.5% of